SONN - Why Sonnet BioTherapeutics (SONN) Stock Is Getting Hammered | Benzinga
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 27.6% to $1.31 Wednesday morning after the company announced the pricing of a public offering involving 2,843,750 shares of common stock or pre-funded warrants, along with investor warrants allowing the purchase of up to 5,687,500 shares of common stock.
What Else?
Sonnet BioTherapeutics ...
SONN) Stock Is Getting Hammered>Full story available on Benzinga.com